The new World Ocean Review: Explaining life in the ocean
more
Stories about Genetik
Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030
Suresnes, France (ots/PRNewswire) - - Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. - Growth over the financial year was driven by increased sales in oncology, particularly in the United States. - Several partnership agreements in oncology and neurology strengthen the Group's R&D portfolio in rare diseases. - Achieving 2025 ...
morePress Release: STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe
STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe - European Commission approves STADA’s Kefdensis® and Zvogra® denosumab biosimilars for all indications of reference medicines Prolia® and ...
3 DocumentsmoreAsklepios Kliniken GmbH & Co. KGaA
Hessian Minister President Boris Rhein presents the Broermann Medical Innovation Award
Wiesbaden, Germany (ots) - - Dr. Carl June and Dr. Michel Sadelain honored for groundbreaking CAR-T cell research in cancer therapy - One of the world’s most highly endowed medical prizes, with €1 million in prize money, awarded for the first time - Titia große Broermann: “With the Broermann Medical Innovation Award, we want to make outstanding medical ...
moreKerry Establishes New Biotechnology Centre in Leipzig / Centre to facilitate cutting-edge innovations with wide range of applications across food, beverage and pharma
Leipzig (ots) - Kerry, a global leader in taste and nutrition, has today inaugurated the Kerry Biotechnology Centre in Leipzig, Germany, which will focus on the development of innovative biotech solutions across food, beverage, and pharma applications. New capabilities in biotechnology are opening the field to ...
moreAsklepios Kliniken GmbH & Co. KGaA
2Dr. Carl June and Dr. Michel Sadelain are being awarded the Broermann Medical Innovation Award 2025
more
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Suresnes, France (ots/PRNewswire) - - Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company - KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA - Acquisition ...
more- 2
New Endoscopy Technology Enables Early Detection of Esophageal Cancer
more Therapeutic Vaccine for Chronic Hepatitis B Enters First Clinical Trial in Patients
moreCancer Cachexia: Liver Identified as Driver of Body Wasting
Many people with cancer experience dramatic loss of muscle and fat tissue. In many cases, even the heart muscle is affected, which further weakens the body. This wasting syndrome, known as cachexia, affects around half of all cancer patients. It is a major cause of therapy resistance, complications, and increased mortality. ...
more- 2
New Label-Free Imaging Tracks Cancer Treatment in Single Cells
more Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
New York and North Chicago, Ill. (ots/PRNewswire) - - ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an ...
more
Fraunhofer-Institut für Produktionstechnologie IPT
Transforming personalized medicine with AI-driven CAR-T manufacturing: Automated CAR-T cell production platform is ready for production
moreInnovative Molecules Completes Enrollment of Phase 1b Clinical Trial of IM-250
Munich (ots/PRNewswire) - Innovative Molecules GmbH Announces Completion of Phase 1b Enrollment for IM-250 in Genital Herpes Clinical Trial Innovative Molecules GmbH today announced the completion of enrollment in the Phase 1b portion of its ongoing Phase 1b/2a clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor targeting herpes simplex virus ...
more- 3
Key technology for bioprocesses
more BIAL Announces Oral Presentation at GBA1 Meeting 2025
Porto, Portugal (ots/PRNewswire) - BIAL, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that it will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held June 5-7, 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1 research, from basic ...
moreASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
Petach Tikva, Israel (ots/PRNewswire) - ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential ...
moreNeutroFlow: Leading European Medical Consortium Awarded €2.5 Million Grant from EIC Transition Programme to Advance Predictive Biomarker Development for Immunotherapy Response
Heidelberg, Germany, Milan, Seville, Spain and Binyamina, Israel (ots/PRNewswire) - A European-led consortium comprising Heidelberg University Hospital (UKHD), the European Institute of Oncology (IEO), Virgen Macarena University Hospital, and OncoHost today announced that it has been awarded a €2.5 million grant ...
more
Biomay Launches FDA-Grade CRISPR/Cas9 Nuclease for Off-the-Shelf Purchase
Vienna, Austria (ots) - Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing applications. Clients purchasing Biomay´s Cas9 will benefit from the company´s unparalleled track record and expertise as a ...
moreTechnische Universität München
Identifying pathogens within minutes instead of days
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Mass spectrometry detects bacteria without time-consuming isolation and multiplication Identifying pathogens within minutes instead of days - Identification directly in tissue and stool samples - So far 232 medically important bacterial species detectable - Database must now be further expanded Speed and reliability are crucial in the diagnosis of diseases. Researchers at the ...
moreBiomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site
moreEngineering Smart Delivery for Gene Editors
more- 2
GEA presents the kytero® 10, the world's smallest single use disk stack centrifuge
more New Knowledge Portal Adiposetissue.org Enhances Obesity and Metabolism Research with Centralized Data
more
CO.DON GmbH partners in EU-Funded Project to Advance 3D Bioprinting for Tissue Regeneration
Teltow (ots) - The EU-funded micro2MACRO (m2M) project, launched in December 2024, aims to advance tissue regeneration through an innovative bioprinting platform. m2M focuses on precisely patterning cell aggregates and microtissues into stable, customizable grafts that remodel into functional tissues after implantation. The project unites leading academic institutions, ...
moreAncient Viral DNA Shapes Early Embryo Development
Over half of our genomes consists of thousands of remnants of ancient viral DNA, known as transposable elements, which are widespread across the tree of life. Once dismissed as the "dark side" of the genome, researchers at Helmholtz Munich and Ludwig-Maximilians-Universität (LMU) have now revealed their crucial role in early embryo development. Unanswered Questions About the Role of Ancient Viral DNA Transposable ...
moreLTS Lohmann Therapie-Systeme AG
LTS wins funding from BARDA’s Patch Forward Prize Competition for two partnerships
moreSCP-Nano: A New Technology to Visualize Nanocarriers in Cells and Tissues
moreRHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers
moreMaria-Elena Torres-Padilla Honored With the Leibniz Prize 2025
more
123456Next